Radiolabeling of monoclonal antibodies (mAbs) with an intracellularly trapped form of 131I
(residualizing 131I) involves radioiodinating a small molecular entity, conjugating it to the …

Purpose: A disadvantage of conventionally radioiodinated monoclonal antibodies (mAb) for
cancer therapy is the short retention time of the radionuclide within target cells. To address …

BACKGROUND The initial clinical experience with the second‐generation, high‐affinity, MN‐
14 immunoglobulin (IgG) anticarcinoembryonic antigen (CEA) monoclonal antibody (MoAb) …

The biodistribution, pharmacokinetics and dosimetry of^ Re labeled MN-14, an IgG anti-
carcinoembryonic antigen monoclonal antibody (MAb), were assessed in patients in …

Background. The authors previously reported that an anticarcinoembryonic antigen antibody
against a carcinoembryonic antigen (CEA)‐specific epitope is preferred for clinical …

This trial was conducted to determine the pharmacokinetics, dosimetry, dose-limiting toxicity,
and the maximum tolerated dose of iodine-131 humanized MN-14 immunoglobulin G (131I …

Therapeutic efficacy in radioimmunotherapy depends, among other things, on the choice of
the radionuclide. The aim of the present study was to determine the most suitable …

This study reports on the in vitro evaluation, biodistribution, and dosimetry of 123I-labeled
monoclonal antibody (mAb) 14C5, a new antibody-based agent proposed for …

A novel, facile procedure for efficient coupling of high doses of 131I to monoclonal
antibodies (MAbs) was developed with minimal chemical and radiation damage. Methods …

A complementarity-determining region-grafted (humanized) version of MN-14 (hMN-14), a
high-affinity, anti-carcinoembryonic antigen (CEA) murine monoclonal antibody (mMAb) …